Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study

Candel Therapeutics, Inc.’s (CADL) shares skyrocketed 280.9% on Apr 5, after the company announced positive interim data from the phase II study evaluating its lead candidate, CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC).The updated interim data from the ongoing phase II study showed that experimental treatment with CAN-2409 led to notable improvements in estimated median ove ...